BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

397 related articles for article (PubMed ID: 25465376)

  • 21. High expression of proline-rich tyrosine kinase 2 is associated with poor survival of hepatocellular carcinoma via regulating phosphatidylinositol 3-kinase/AKT pathway.
    Cao J; Chen Y; Fu J; Qian YW; Ren YB; Su B; Luo T; Dai RY; Huang L; Yan JJ; Wu MC; Yan YQ; Wang HY
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S312-23. PubMed ID: 22618716
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IMP3 combined with CD44s, a novel predictor for prognosis of patients with hepatocellular carcinoma.
    Hu S; Wu X; Zhou B; Xu Z; Qin J; Lu H; Lv L; Gao Y; Deng L; Yin J; Li G
    J Cancer Res Clin Oncol; 2014 Jun; 140(6):883-93. PubMed ID: 24647926
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epithelial to mesenchymal transition is associated with shorter disease-free survival in hepatocellular carcinoma.
    Yamada S; Okumura N; Wei L; Fuchs BC; Fujii T; Sugimoto H; Nomoto S; Takeda S; Tanabe KK; Kodera Y
    Ann Surg Oncol; 2014 Nov; 21(12):3882-90. PubMed ID: 24833103
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chromobox homolog 4 is correlated with prognosis and tumor cell growth in hepatocellular carcinoma.
    Wang B; Tang J; Liao D; Wang G; Zhang M; Sang Y; Cao J; Wu Y; Zhang R; Li S; Ding W; Zhang G; Kang T
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S684-92. PubMed ID: 23943028
    [TBL] [Abstract][Full Text] [Related]  

  • 25. miR-192, a prognostic indicator, targets the SLC39A6/SNAIL pathway to reduce tumor metastasis in human hepatocellular carcinoma.
    Lian J; Jing Y; Dong Q; Huan L; Chen D; Bao C; Wang Q; Zhao F; Li J; Yao M; Qin L; Liang L; He X
    Oncotarget; 2016 Jan; 7(3):2672-83. PubMed ID: 26684241
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Differential expression of IQGAP1/2 in Hepatocellular carcinoma and its relationship with clinical outcomes.
    Xia FD; Wang ZL; Chen HX; Huang Y; Li JD; Wang ZM; Li XY
    Asian Pac J Cancer Prev; 2014; 15(12):4951-6. PubMed ID: 24998570
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical significance of PICT1 in patients of hepatocellular carcinoma with wild-type TP53.
    Ishibashi M; Kogo R; Shibata K; Ueo H; Uchi R; Matsumura T; Takano Y; Sawada G; Takahashi Y; Mima K; Kurashige J; Akiyoshi S; Iwaya T; Eguchi H; Sudo T; Sugimachi K; Suzuki A; Wakabayashi G; Mori M; Mimori K
    Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S537-44. PubMed ID: 23532381
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatoma-derived growth factor/nucleolin axis as a novel oncogenic pathway in liver carcinogenesis.
    Chen SC; Hu TH; Huang CC; Kung ML; Chu TH; Yi LN; Huang ST; Chan HH; Chuang JH; Liu LF; Wu HC; Wu DC; Chang MC; Tai MH
    Oncotarget; 2015 Jun; 6(18):16253-70. PubMed ID: 25938538
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prediction of recurrence and survival in hepatocellular carcinoma based on two Cox models mainly determined by FoxP3+ regulatory T cells.
    Lin SZ; Chen KJ; Xu ZY; Chen H; Zhou L; Xie HY; Zheng SS
    Cancer Prev Res (Phila); 2013 Jun; 6(6):594-602. PubMed ID: 23599540
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Downregulation of SLC5A8 inhibits hepatocellular carcinoma progression through regulation of Wnt/β-catenin signaling.
    Hu BS; Xiong SM; Li G; Li JP
    Tumour Biol; 2016 Oct; 37(10):13445-13453. PubMed ID: 27465549
    [TBL] [Abstract][Full Text] [Related]  

  • 31. High expression of IL-9R promotes the progression of human hepatocellular carcinoma and indicates a poor clinical outcome.
    Li HJ; Sun QM; Liu LZ; Zhang J; Huang J; Wang CH; Ding R; Song K; Tong Z
    Oncol Rep; 2015 Aug; 34(2):795-802. PubMed ID: 26082242
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of TREM-1 in hepatic stellate cells and prognostic value in hepatitis B-related hepatocellular carcinoma.
    Liao R; Sun TW; Yi Y; Wu H; Li YW; Wang JX; Zhou J; Shi YH; Cheng YF; Qiu SJ; Fan J
    Cancer Sci; 2012 Jun; 103(6):984-92. PubMed ID: 22417086
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma.
    Chiba T; Saito T; Yuki K; Zen Y; Koide S; Kanogawa N; Motoyama T; Ogasawara S; Suzuki E; Ooka Y; Tawada A; Otsuka M; Miyazaki M; Iwama A; Yokosuka O
    Int J Cancer; 2015 Jan; 136(2):289-98. PubMed ID: 24844570
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High expression of TRIM44 is associated with enhanced cell proliferation, migration, invasion, and resistance to doxorubicin in hepatocellular carcinoma.
    Zhu X; Wu Y; Miao X; Li C; Yin H; Yang S; Lu X; Liu Y; Chen Y; Shen R; Chen X; He S
    Tumour Biol; 2016 Nov; 37(11):14615-14628. PubMed ID: 27619678
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Overexpression of HnRNP A1 promotes tumor invasion through regulating CD44v6 and indicates poor prognosis for hepatocellular carcinoma.
    Zhou ZJ; Dai Z; Zhou SL; Fu XT; Zhao YM; Shi YH; Zhou J; Fan J
    Int J Cancer; 2013 Mar; 132(5):1080-9. PubMed ID: 22821376
    [TBL] [Abstract][Full Text] [Related]  

  • 36. miR-122 targets pyruvate kinase M2 and affects metabolism of hepatocellular carcinoma.
    Liu AM; Xu Z; Shek FH; Wong KF; Lee NP; Poon RT; Chen J; Luk JM
    PLoS One; 2014; 9(1):e86872. PubMed ID: 24466275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of miR-152 on cell growth inhibition, motility suppression and apoptosis induction in hepatocellular carcinoma cells.
    Dang YW; Zeng J; He RQ; Rong MH; Luo DZ; Chen G
    Asian Pac J Cancer Prev; 2014; 15(12):4969-76. PubMed ID: 24998573
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ACK1 promotes hepatocellular carcinoma progression via downregulating WWOX and activating AKT signaling.
    Xie B; Zen Q; Wang X; He X; Xie Y; Zhang Z; Li H
    Int J Oncol; 2015 May; 46(5):2057-66. PubMed ID: 25738261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma.
    Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ
    Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853
    [TBL] [Abstract][Full Text] [Related]  

  • 40. SIRT1 promotes tumorigenesis and resistance to chemotherapy in hepatocellular carcinoma and its expression predicts poor prognosis.
    Chen HC; Jeng YM; Yuan RH; Hsu HC; Chen YL
    Ann Surg Oncol; 2012 Jun; 19(6):2011-9. PubMed ID: 22146883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.